[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
A N BoykoValentina M AlifirovaI G LukashevichZoya A GoncharovaI V GreshnovaL G ZaslavskyS V KotovN A MalkovaG N MishinYe V ParshinaI Ye PoverennovaL N PrakhovaStella SivertsevaI V SmaginaN A TotolyanYu V TrinitatskyT N TrushnikovaF A KhabirovZh Yu ChefranovaS G ShchurV A DudinD V PokhabovA V ArtemevaAnna V EremeevaYulia N LinkovaArina V Zinkina-OrikhanPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase iii
- phase ii
- multiple sclerosis
- end stage renal disease
- study protocol
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- computed tomography
- prognostic factors
- stem cells
- squamous cell carcinoma
- magnetic resonance
- randomized controlled trial
- image quality
- dual energy
- patient reported outcomes
- bone marrow
- cell therapy
- patient reported
- combination therapy